Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Intech Investment Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) in ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...

PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) has received a consensus recommendation of “Moderate Buy ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

Today, Benzinga's options scanner spotted 25 options trades for Teva Pharmaceutical Indus. This is not a typical pattern. The sentiment among these major traders is split, with 24% bullish and 60% ...

Last year, we took bold steps to ensure our sites were addressing antimicrobial resistance (AMR) throughout the entire ...

We recently published a list of 12 Best Stocks Under $25 To Invest In Right Now. In this article, we are going to take a look ...

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well ...